Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 320 participants.
Also called NCT05321875
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 320 participants
- Sponsor
- Cristina Avendaño Solá
- Registry
-
NCT05321875 -
2021-004577-30
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT05321875. Randomized; quadruple masking; primary purpose prevention. Start 2022-06-02 (actual); primary completion 2026-06-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)
- Acronym
- EARLY-GENE
- Condition
- Cardiomyopathy, Dilated
- Intervention (Drug)
- Candesartan
- Lead sponsor
- Cristina Avendaño Solá
Record details
- Record id
cardio:ct-nct05321875- Content hash
43f26f50396fecedfbdf1cf8539303e67545248556c86cf79e58b7c2de45a8a6